Skip to main content

Harmony Biosciences Holdings Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Three Months Ended June 30, · ​ · Six Months Ended June 30,
​ · 2024 · 2023 · 2024 · 2023
Net product revenue​$172,814​$134,216​$327,429​$253,342
Cost of product sold​32,144​25,008​59,628​45,788
Gross profit​140,670​109,208​267,801​207,554
Operating expenses:​​​​
Research and development​63,583​14,969​85,772​28,258
Sales and marketing​28,507​24,528​55,740​47,100
General and administrative​27,224​22,809​52,900​44,871
Total operating expenses​119,314​62,306​194,412​120,229
Operating income​21,356​46,902​73,389​87,325
Other (expense) income, net​37​(31)​(104)​(29)
Interest expense​​(4,404)​​(6,218)​​(8,939)​(11,949)
Interest income​4,705​3,442​9,133​6,528
Income before income taxes​21,694​44,095​73,479​81,875
Income tax expense​(10,103)​(9,795)​(23,554)​(18,090)
Net income​$11,591​$34,300​$49,925​$63,785
Unrealized (loss) income on investments​(63)​(491)​(236)​(371)
Comprehensive income​$11,528​$33,809​$49,689​$63,414
EARNINGS PER SHARE:​​​​
Basic​$0.20​$0.57​$0.88​$1.07
Diluted​$0.20​$0.56​$0.87​$1.05
Weighted average number of shares of common stock - basic​56,802,357​59,974,123​56,786,873​59,853,808
Weighted average number of shares of common stock - diluted​57,541,696​60,743,953​57,571,570​60,997,410
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.